ଅକ୍ସିକୋଡୋନ

ଉଇକିପିଡ଼ିଆ‌ରୁ
ଅକ୍ସିକୋଡୋନ
Clinical data
Pronunciationɒksɪˈkəʊdəʊn
Trade namesOxyContin, others
SynonymsEukodal, eucodal; dihydrohydroxycodeinone, 7,8-dihydro-14-hydroxycodeinone, 6-deoxy-7,8-dihydro-14-hydroxy-3-O-methyl-6-oxomorphine [୨]
AHFS/Drugs.commonograph
MedlinePlusa682132
Pregnancy
category
  • AU: C
  • US: B (No risk in non-human studies)
Dependence
liability		High
Routes of
administration		By mouth, sublingual, intramuscular, intravenous, intranasal, subcutaneous, transdermal, rectal, epidural [୧]
ATC code
Legal status
Legal status
Pharmacokinetic data
BioavailabilityBy mouth: 60–87%[୩][୫]
Protein binding45%[୩]
MetabolismLiver: mainly CYP3A, and, to a much lesser extent, CYP2D6 (~5%);[୩] 95% metabolized (i.e., 5% excreted unchanged)[୪]
Metabolites• Noroxycodone (25%) [୬][୪]
• Noroxymorphone (15%, free and conjugated)[୬][୪]
• Oxymorphone (11%, conjugated)[୬][୪]
• Others (e.g., minor metabolites)[୪]
Onset of actionIR: 10–30 minutes[୫][୪]
CR: 1 hour[୭]
Elimination half-lifeBy mouth (IR): 2–3 hrs (same t1/2 for all ROAs)[୪][୫]
By mouth (CR): 4.5 hrs[୮]
Duration of actionBy mouth (IR): 3–6 hrs[୪]
By mouth (CR): 10–12 hrs[୯]
ExcretionUrine (83%)[୩]
Identifiers
  • (5R,9R,13S,14S)-4,5α-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
ECHA InfoCard100.000.874 Edit this at Wikidata
Chemical and physical data
FormulaC18H21NO4
Molar mass315.364 g/mol
3D model (JSmol)
Melting point219 °C (426 °F)
Solubility in waterHCl: 166 mg/mL (20 °C)
  • O=C4[C@@H]5Oc1c2c(ccc1OC)C[C@H]3N(CC[C@]25[C@@]3(O)CC4)C
  • InChI=1S/C18H21NO4/c1-19-8-7-17-14-10-3-4-12(22-2)15(14)23-16(17)11(20)5-6-18(17,21)13(19)9-10/h3-4,13,16,21H,5-9H2,1-2H3/t13-,16+,17+,18-/m1/s1 checkY
  • Key:BRUQQQPBMZOVGD-XFKAJCMBSA-N checkY
  (verify)

ଅକ୍ସିକୋଡୋନ (ଇଂରାଜୀ ଭାଷାରେ Oxycodone, ଏକ ବିକ୍ରୟ ନାମ ଅକ୍ସିକୋଣ୍ଟିନ/ OxyContin) ଏକ ଓପିଅଏଡ (opioid) ଔଷଧ ଯାହା ମଧ୍ୟମ ଓ ସାଂଘାତିକ ଧରଣ ଯନ୍ତ୍ରଣା (pain) ଲାଘବ ନିମନ୍ତେ ଦିଆଯାଏ ।[୧୦] ଏହି ଔଷଧ ପାଟିରେ (by mouth) ଦିଆଯାଏ ଓ ଏହା ତୁରନ୍ତ ବିମୋଚନ (immediate release) ଓ ନିୟନ୍ତ୍ରିତ ବିମୋଚନ (controlled release) ଫର୍ମୁଲାରେ ମିଳେ ।[୧୦] ତୁରନ୍ତ କାର୍ଯ୍ୟକ୍ଷମ ଔଷଧ ଦେବାର ୧୫ ମିନିଟ ମଧ୍ୟରେ କଷ୍ଟ ଲାଘବ ଆରମ୍ଭ ହୋଇ ପ୍ରାୟ ୬ ଘଣ୍ଟା ପର୍ଯ୍ୟନ୍ତ କାମ କରେ ।[୧୦] ସଂଯୁକ୍ତ ରାଷ୍ଟ୍ରରେ (United Kingdom) ଏହା ଇଞ୍ଜେକସନ (by injection) ଆକାରରେ ମିଳେ ।[୧୧] ଅନ୍ୟ ଔଷଧ ଯେପରିକି ପାରାସେଟାମୋଲ ବା ଆସ୍ପିରିନ ସାଥିରେ ମିଶ୍ରିତ ଔଷଧ (Combination product) ଆକାରରେ ମଧ୍ୟ ଏହା ମିଳେ ।[୧୦]

ଅକ୍ସିକୋଡୋନର ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ କୋଷ୍ଠକାଠିନ୍ୟ, ଅଇ (nausea), ନିଦ୍ରାଳୁ ଭାବ, ମୁଣ୍ଡ ଓଜନିଆ (dizziness), ଗଲୁ (itching), ଶୁଷ୍କ ପାଟି (dry mouth) ଓ ସ୍ୱେଦ ନିର୍ଗତ (sweating) ଇତ୍ୟାଦି ହୋଇପାରେ ।[୧୦] ସାଂଘାତିକ ପ୍ରତିକ୍ରିୟା ହେଲେ ଔଷଧ ନିଶା (addiction), ନ୍ୟୁନ ଶ୍ୱାସକ୍ରିୟା (respiratory depression) ଓ ସ୍ୱଳ୍ପ ରକ୍ତଚାପ (low blood pressure) ଇତ୍ୟାଦି ହୋଇପାରେ । [୧୦] କୋଡିନ (codeine) ପ୍ରତି ଆଲର୍ଜି ଥିଲେ ଅକ୍ସିକୋଡୋନ ପ୍ରତି ମଧ୍ୟ ଆଲର୍ଜି ହୋଇପାରେ । [୧୦] ଗର୍ଭାବସ୍ଥାର ପ୍ରଥମ ଭାଗରେ ଏହା ଅପେକ୍ଷାକୃତ ବିପଦମୁକ୍ତ ।[୧୦] ଏହି ଔଷଧ ଦେବା ହଠାତ୍ ବନ୍ଦ କରିଦେଲେ ଓପିଅଏଡ ଉଇଥଡ୍ରାଅଲ (Opioid withdrawal) ହୋଇପାରେ ।[୧୦] μ-ଓପିଅଏଡ ରିସେପ୍ଟରକୁ (μ-opioid receptor) ଏହା ସକ୍ରିୟ କରିଦିଏ ।[୧୨] ସମ ପରିମାଣର ଅଫିମ (morphine) ଅପେକ୍ଷା ଏହା ୧.୫ଗୁଣା ପ୍ରଭାବ ପକାଇପାରେ ।[୧୩]

ଜର୍ମାନୀରେ ସନ ୧୯୧୬ରେ ପ୍ରଥମେ ଥିବେନରୁ (thebaine) ଅକ୍ସିକୋଡୋନ ପ୍ରସ୍ତୁତ କରାଯାଇଥିଲା । [୧୪] ଏହା ଜେନେରିକ ଔଷଧ ନାମରେ (generic medication) ବିକ୍ରୟ ହୁଏ ।[୧୦] ସନ ୨୦୧୮ରେ ଯୁକ୍ତରାଷ୍ଟ୍ର ଆମେରିକାରେ ଏହାର ଏକ ଡୋଜର ହୋଲସେଲ ମୂଲ୍ୟ ୦.୩୦ ଆମେରିକୀୟ ଡଲାରରୁ କମ୍ ଥିଲା । [୧୫] ସନ ୨୦୧୬ରେ ଏହାର ୧୪ ନିୟୁତ ପ୍ରେସକ୍ରିପସନ ହୋଇ ୫୪ତମ ସର୍ବାଧିକ ପ୍ରେସକ୍ରିପସନର ମାନ୍ୟତା ପାଇଥିଲା ।[୧୬] ଏହା ଏକ ସାଧାରଣ ନିଶାଦ୍ରବ୍ୟ (drug of abuse) ଭାବରେ ବ୍ୟବ‌ହାର କରାଯାଏ ।[୧୭] ଏହା ସହିତ ନାଲୋକ୍ସୋନ ମିଶ୍ରିତ ନିଶା ନିବାରକ ଅକ୍ସିକୋଡୋନ/ନାଲୋକ୍ସୋନ (combination with naloxone) ଫର୍ମୁଲା ମିଳୁଛି ।[୧୭][୧୮]

ଆଧାର[ସମ୍ପାଦନା]

  1. ↑ Kalso E (2005). "Oxycodone". Journal of Pain and Symptom Management. 29 (5S): S47–S56. doi:10.1016/j.jpainsymman.2005.01.010. PMID 15907646.
  2. ↑ O'Neil, Maryadele J., ed. (2006). The Merck index (14 ed.). Whitehouse Station, NJ: Merck & Co. ISBN 978-0-911910-00-1.
  3. ↑ ୩.୦ ୩.୧ ୩.୨ ୩.୩ "Roxicodone, OxyContin (oxycodone) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 8 April 2014.
  4. ↑ ୪.୦ ୪.୧ ୪.୨ ୪.୩ ୪.୪ ୪.୫ ୪.୬ ୪.୭ Howard Smith; Steven Passik (25 April 2008). Pain and Chemical Dependency. Oxford University Press USA. pp. 195–. ISBN 978-0-19-530055-0.
  5. ↑ ୫.୦ ୫.୧ ୫.୨ Jennifer A. Elliott; Howard S. Smith (19 April 2016). Handbook of Acute Pain Management. CRC Press. pp. 82–. ISBN 978-1-4665-9635-1.
  6. ↑ ୬.୦ ୬.୧ ୬.୨ "Roxicodone, OxyContin (oxycodone) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 4 January 2019.
  7. ↑ Connie Henke Yarbro; Debra Wujcik; Barbara Holmes Gobel (15 November 2010). Cancer Nursing: Principles and Practice. Jones & Bartlett Publishers. pp. 695–. ISBN 978-1-4496-1829-2.
  8. ↑ Richard A. McPherson; Matthew R. Pincus (31 March 2016). Henry's Clinical Diagnosis and Management by Laboratory Methods. Elsevier Health Sciences. pp. 336–. ISBN 978-0-323-41315-2.
  9. ↑ Sunshine, Abraham; Olson, Nancy Z.; Colon, Ariel; Rivera, Juana; Kaiko, Robert F.; Fitzmartin, Ronald D.; Reder, Robert F.; Goldenheim, Paul D. (July 1996). "Analgesic Efficacy of Controlled-Release Oxycodone in Postoperative Pain". Journal of Clinical Pharmacology. 36 (7): 595–603. doi:10.1002/j.1552-4604.1996.tb04223.x. PMID 8844441. Treatment with CR oxycodone was safe and effective in this study, and its characteristics will be beneficial in the treatment of pain.
  10. ↑ ୧୦.୦୦ ୧୦.୦୧ ୧୦.୦୨ ୧୦.୦୩ ୧୦.୦୪ ୧୦.୦୫ ୧୦.୦୬ ୧୦.୦୭ ୧୦.୦୮ ୧୦.୦୯ "Oxycodone Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). AHFS. Retrieved 28 December 2018.
  11. ↑ British national formulary : BNF 74 (74 ed.). British Medical Association. 2017. p. 442. ISBN 978-0857112989.
  12. ↑ Nicholas J Talley; Brad Frankum; David Currow (10 February 2015). Essentials of Internal Medicine 3e. Elsevier Health Sciences. pp. 491–. ISBN 978-0-7295-8081-6.
  13. ↑ "Stanford School of Medicine, Palliative Care, Opioid Conversion / Equivalency Table". 2013-04-20. Archived from the original on 2020-09-09. Retrieved 2019-03-03. {{cite journal}}: Cite journal requires |journal= (help)
  14. ↑ Sneader, W. (2005). Drug discovery: a history. Hoboken, NJ: Wiley. p. 119. ISBN 978-0-471-89980-8.
  15. ↑ "NADAC as of 2018-12-19". Centers for Medicare and Medicaid Services (in ଇଂରାଜୀ). Archived from the original on 2018-12-19. Retrieved 22 December 2018.
  16. ↑ "The Top 300 of 2019". clincalc.com. Retrieved 22 December 2018.
  17. ↑ ୧୭.୦ ୧୭.୧ Pergolizzi JV, Jr; Taylor R, Jr; LeQuang, JA; Raffa, RB (2018). "Managing severe pain and abuse potential: the potential impact of a new abuse-deterrent formulation oxycodone/naltrexone extended-release product". Journal of Pain Research. 11: 301–311. doi:10.2147/JPR.S127602. PMC 5810535. PMID 29445297.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  18. ↑ Dart, RC; Iwanicki, JL; Dasgupta, N; Cicero, TJ; Schnoll, SH (2017). "Do abuse deterrent opioid formulations work?". Journal of Opioid Management. 13 (6): 365–378. doi:10.5055/jom.2017.0415. PMID 29308584.

ଅଧିକ ପଢ଼ନ୍ତୁ[ସମ୍ପାଦନା]

"https://or.wikipedia.org/w/index.php?title=ଅକ୍ସିକୋଡୋନ&oldid=505660"ରୁ ଅଣାଯାଇଅଛି